Проведено открытое исследование влияния ИФ-а (1õ10 6 ME) на ксеростомию у 10 больных с синдромом Шегрена (S. Shiozawa и соавт., 1993). У 6 больных на фоне лечения отмечен определенный клинический эффект.

В отдельных клинических наблюдениях описаны положительные результаты лечения ИФ-а язвенного поражения слизистой полости рта при болезни Бехчета (V. Hamuryudan и соавт., 1990) и глазных проявлений заболевания (J. M. Durand и соавт., 1993).

При проведении лечения препаратами ИФ (особенно ИФ-а) необходимо помнить об их потенциальной способности индуцировать развитие волчаночноподобных синдромов (L. E. Ronnblom и соавт., 1990; P. J. Schilling и соавт., 1991; L. E. Ronnblom и соавт., 1991), артрита (Y. Ueno и соавт., 1992; P. D. W. Kielly и F. E. Bruckner, 1994) или серологических нарушений, характерных для СКВ (M. R. Ehrenstein и соавт., 1993).

Таким образом, в настоящее время в ревматологии используется широкий спектр методов иммунотерапии, однако для окончательного ответа на вопрос о месте того или иного подхода в лечении определенных аутоиммунных ревматических заболеваний необходимы специальные контролируемые исследования больших групп больных и в течение длительного времени. Последнее особенно важно для оценки влияния новых методов лечения на отдаленный прогноз заболеваний и развитие отсроченных побочных эффектов, связанных с длительной иммуносупрессией, в первую очередь инфекционных осложнений и онкологической патологии.

Список литературы к главе "Иммунотерапия в ревматологии"

1.Arend W. P., Smith M. F., Janson R. W., Joslin F. G.: IL-I receptor antagonist and IL-I beta production in human monocytes are regulated differently. J. Immunol. 1991; 147: 1530-1535.

2.Auffray С., Pitatier-Tonneau D., Kroemer G.: CD4-target immune intervention: a strategy for the therapy of AIDS and autoimmune disease. Trends Biotech. 1991; 9: 124-131.

3.Breedveld F. C., De Vries R. R. P.: Anti-CD4 antibodies in rheumatoid arthritis. Clin. Exp. Rheumatol. 1992; 10: 325-326.

4.Brennan F. M., Maini R. N., Feidman M.: TNF-alpha — a pivotal role in rheumatoid arthritis. Brit. J. Rheumatol., 1992; 31: 293-298.

5.Browning J.: Interferons and rheumatoid arthritis: Insight into interferon biology?. Immunol. Today 1987; 8: 372-374.

6.Burmester G. R., Emmrich F.: Anti-CD4 therapy in rheumatoid arthritis. Clin. Exp. Rheumatol., 1993; II (Suppl. 8): S139-S145

7.Byers V. S., Henslee P. J., Blazar B. D. et al.: Use of anti-pan-T lymphocyte ricin A immune toxin in steroid resistant acute graft-versus-host disease. Blood. 1990; 75: 1462-1432.

8.Campion G.,Witt K., Musikis P. et al.: The effect of dose and dose frequency on disease activity in patients with rheumatoid arthritis (RA) with the subcutaneous administration of recombinant human Interleukin receptor antagonist (anakira). Brit. J. Rheumatol., 1994. (Suppl. 1); 33: 182.

9.Cannon G. W., Schindler J. D., Emkey R. D. et al.: Double-blind trial of recombinant inter-feron- gamma versus placebo in rheumatoid arthritis. Arthritis Rheum. 1987; 30 (suppl.): S-18.

10.Cannon G. W., Emkey R. D., Denes A. et al.: Prospective two-year following of recombinant interferongamma in rheumatoid arthritis. J. Rheumatol. 1990; 17 (suppl. 30): 304-310.

11.Choy E., Adjaye J., Kingsiey G., Panayi G.: Chimeric anti-CD4 antibody acts by causing apoptosis (programmed cell death) of human lymphocytes. Arthritis Rheum., 1992; 35: S44 (abst.).

12.Choy E. H. S., Chicanza I. C., Kingsley G. H. et al. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimeric anti-CD4 monoclonal antibody. Scand. J. Immunol., 1992; 36: 291-298.

13.Choy E. H. S., Pitxalis C., Bijl J. A. et al. The importance of dose and dosing regimen of anti-CD4 monoclonal antibody (mAb) in the treatment of rheumatoid arthritis. Brit. J. Med., 1994. (Suppl. 1); 33: 294.

14.Choy E. H. S., Chikanza I. C., Kingsley G. H., Panayi G. S.: Chimeric anti-CD4 monoclonal antibody for relapsing polychondritis. Lancet, 1991; 338: 450.

15.Cohen P., Nguyen Q. T., Roulot D. et al.: Treatment od essential mixed cryoglobulinemia by interferon alpha. An open multicenter prospective trial. Arthritis Rheum. 1994; 37 (Suppl.): S270.

16.Dreviow B., Capezio J., Lovis R. et al. Phase I study of recombinant human interleukin-I receptor (rhu IIIR) administered intra-articulary in active rheumatoid arthritis. , Arthritis Rheum. 1993; 36 (suppl.): S-39.

17.Durand J. M., Kaplanski G., Soubeyrand J.: Beneficial effects of interferon-alfa2b in Behcet's disease. Arthritis Rheum. 1993; 36: 1025-1026.

18.Ehrenstein M. R., McSween E., Swana M. et al.: Appearance of anti-DNA antibodies in patients treated with interferon-alpha. Artritis Rheum. 1993; 36: 279-280.

19.Elliott M., Maini R. N., Feldman M. et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alfa. Arthritis Rheum. 1993. 36: 1681-1690.

20.Elliot M. J., Maini R. N., Feldman M. et al.: Randomised double-blind comparison of chimeric monoclonal

antibody to tumar necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-1110.

21.Elliott M. J., Maini R. N., Feldmann M. et al.: Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rtheumatoid arthritis. Lancet 1994; 344: 1125-1127.

22.Ferrazi V., Jorgensen С., Sany J.: Alpha-interferon therapy for leukemia or active viral hepatitis in patients with rheumatoid arthritis. Arthritis Rheum. 1994; 27 (suppl.): S-246.

23.Ferri C., La Civita L., Longombardo G. et al.: Treatment of mixed cryoglobulinemia by alpha-interferon: a controled crossover trial. XVIII ILAR Cogr. Rheumatol., 1993; 454 (abst.): 208.

24.Firestein G. S., Alvaro-Garcia J. M., Maki R.: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 1990; 144: 3347-3353.

25.Freundlich В., Jimenez S. A., Steen V. et al.: Treatment of systemic sclerosis with recom-binant interferongamma: a phase I/II clinical trial. Arthritis Rheum., 1992; 35: 1134-1142.

26.Hale G., Xia M.-Q., Tighe H. P. et al.: The CAMPATH-1H antigen (CDw52). Tissue antigens 1990; 35: 118-127.

27.Hamuryudan V., Yurdakul S., Serdaroglu S. et al.: Topical alpha interferon in the treatment of oral ulcers in Behcet's syndrome: a preliminary report. Clin. Exp. Rheumatol. 1990; 8: 51-54.

28.Hamuryudan V., Morab F., Yurdakui S. et al.: Systemic interferon alpha2b treatment in Bechcet's syndrome. J. Rheumatol. 1994; 21: 1098-1100.

29.Hiepe E., Thiele B., Brink U. et al.: Succesful treatment of severe systemic lupus erythe-matosus with the anti-CD4 monoclonal antibody max. 16H5. XVIII ILAR Congr. Rheumatol., 1993; 464 (abst.): 212.

30.Horneff G., Krause A., Kalden J. R. et al. Elevated levels of circulating tumor necrosis factor-alpha, interferon-gamma and interleukin 2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis. Cytokine. 1991; 3: 1-2.

31.Horneff G., Burmester G. R., Emmrich F., Kalden J. R.: Treatment of rheumatoid arthritis with anti-CD4 monoclonal antibody. Arthritis Rheum 1991; 36: 291-298.

32.Issacs J. D., Watts R. A., Hazleman B. L., Hale G. et. al.: Humanised monoclonal antybody therapy for rheumatoid arthritis. Lancet 1992; 340: 748-752.

33.Isaacs J. D., Manna V. K., Hazleman B. L. et al.: CAMPATH-1H IN RA A Study of multiple IV dosing. Brit. J. Med. 1994. (Suppl. 1): 33: 154 (abst.).

34.Kahan A., Amor B., Menkes C. J., Strauch G.: Recombinant interferon-gamma In the treatment of systemic sclerosis. Amer. J. Med., 1989; 87: 273-277.

35.Kavanaugh A., Davis L., Nichols L. et al.: Treatment of refractory rheumatoid arthritis with monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 1994; 37: 992-999.

36.Kavanaugh A., Jain R., McFarlin J. et al.: Anti-CD54 (Intercellular adhesion molecule-1; ICAM-1) monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum., 1994; 37 (Suppl.): S220.

37.Keffer J., Probert L., Cazlaris H. et al.: Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991: 10: 4025-4031.

38.Kiely P. D. W., Bruckner F. E.: Acute arthritis following interferon-alpha therapy. Arthritis Rheum. 1994; 33: 502-503.

39.Koopman W. J., Gay S.: Do nonimmunologically mediated pathways play a role in the pathogenesis of rheumatoid arthritis. Rheum. Dis. Clin. North. Amer. 1993; 19: 107-122.

40.Kremer J. M., Petrillo G. F., Rigby W. F. C. et al.: Phase I/II, open trial of DAB398IL-2 administered to patients with active rheumatoid arthritis receiving treatment with methotrexate. Arthritis Rheum. 1994; 37 (suppl.): S-341.

41.Lebsack M. E., Paul C. C., Martindale J. J., Catalano M. A.: A dose and regimen-ranging of IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 1993; 36 (suppl.): S-39.

42.Lemmel E. M., Franke M., Gaus W. et al.: Results of a phase-II clinical trial on the treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol. Int. 1987; 7: 127-132.

43.Lemmel E. M. and German Lymphokine Study Group.: Double blind controlled phase III multicenter study trial with interferon gamma in rheumatoid arthritis. Rheumatol. Int. 1992; 12: 175-185.

44.Machold K. P., Neumann K., Smolen J. S.: Recombinat human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo control study. Ann. Rheum. Dis., 1992; 51: 1039-1043.

45.Margolies L. W., Heck G. R. et al.: Soluble tumor necrosis factor receptor (sTNFR): results of a phase I dose-escalation study in patients with rheumatoid arthritis. Arthritis Rheum.. 1994, (Suppl.): 37: R27.

46.Mathieson P. W., Cobbol S. P., Hale G., Waidman H.: Monoclonal antibody therapy in systemic vasculitis. New Engl. J. Med. 1990; 323: 250-254.

47.Misiani R., Bellavita P., Fenili D. et al.: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis С virus. New Engl. J. Med. 1994; 330: 751-756.

48.Moreland L. W., Pratt P. W., Sanders M. E., Koopman W. J.: Experience with a chimeric monoclonal antiCD4 antibody in the treatment of refractory rheumatoid arthritis. Clin. Exp. Rheumatol. 1993; II (Suppl. 8): S153-S159.

49.Moreland L. W., Heck I. W., Koopman W. J. et al.: Vbl7 T-cell rexeptor vaccine: results of a phase I dose-

finding study in patients with rheumatoid arthritis. Arthritis Rheum. 1994 (Suppl.); 37: S-28.

50.Newell M. K., Haughn L. J., Maroun C. R., Julius M. H.: Death of mature T cells separate ligation of CD4 and the T cell receptor for antigen. Nature 1990; 347: 286-289

51.Noma T, Dorf M. E.: Modulation of supressor T cell induction with gamma-interferon. J. Immunol. 1985;

135:3655-3660.

52.Olsen N. J., Cush J. J., Lipsky P. E. et al.: Multicenter trial of an anti-CD5 immunoconjugate in rheuimatoid arthritis. Arthritis Rheum., 1994; 37 (Suppl.): S295.

53.Panayi G. S., Lanchbury J. S., Kingsley G. H.: The importance of the T cell in initiating and maintaning the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 1992; 35: 729-735.

54.Pincus Т., Callahan L. F.: Remodeling the pyramid or remodeling the paradigm concerning rheumatoid arthritis-lessons from Hodgkin's disease and coronory artery disease. J. Rheumatol. 1990; 17: 1582-1585.

55.Rankin E. C. C., Choy E. H. S., Kassimos D. et al.: A double blind, placebo controlled ascending dose trial of the recombinant humanised anti-TNF alpha antibody CDP571 in patients with rheumatoid arthritis: a preliminary report. Arthritis Rheum., 1994; 37 (Suppl.): S295.

56.Reiter C., Kakavand B., Rieber E. P. et al. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacological effects in an open study, including repeated administration. Arthritis Rheum., 1991; 34: 525-536.

57.Ronnblom L. E., Alm G. V., Oberg K. E.: Possible induction of systemic lupus erythematosus by interferon alpha treatment in patient with a malignant carcinoid tumour. Int. J. Med. 1990; 227: 207-210.

58.Ronnblom L. E., Aim G. V., Oberg K. E.: Autoimmunity after alpha interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 1991; 115: 178-183.

59.Rowe F. M., Edwards J., Cozens P. J.: Increased interleukin-I levels from monocyte of rheumatoid arthritis patients during early stages of the rheumatoid arthritis are down regulated in vitro by the addition of interferon-gamma. J. Leukocyte Biol. 1987; 42: 600-601.

60.Ruschen S., Lemm G., Warnatz H.: Spontaneous and LPS-stimulated production of intra-cellular IL-lbeta by synovial macrophages in rheumatoid arthritis is Inhibited by IFN-gamma. Clin. Exp. Immunol. 1989;

76:246-251.

61.Sewell K. L., Parker K. C., Woodworth T. G. et. al.: DAB486 IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum. 1993; 36: 1223-1233.

62.Sewel K. L., Moreland L. W., Furst D. E. et al.: Phase II, open trial of DAB398IL-2 administered up to four times a year to patients with active rheumatoid arthritis. Arthritis Rheum. 1994; 37 (suppl.): S-341.

63.Shiozawa S., Morimoto I., Tanaka Y., Shiozawa K. A.: Preliminary study on the interferon-alpha treatment for xerostomia of Sjogren's syndrome, Brit. J. Rheumatol. 1993; 32: 52-54.

64.Shiozawa S., Shiozawa К., Kita M. et al. A preliminary study of the effect of alpha-interferon treatment on the joint inflammation and serum calcium in rheumatoid arthritis. Brit. J. Rheumatol. 1992; 31: 405-408.

65.Soriano E., Davies J., Maddison P. J., Hall N. D. Preliminary experience with single infusion Campath-1H in the treatment of refractory rheumatoid arthritis. rit. J. Rheumatol. 1993 (Suppll); 32: 54 (abst.).

66.Steinman L.: The use of monoclonal antibodies for the treatment of autoimmune disease J. Clin. Immunol. 1990; 10 (suppl. 6): S30-S38.

67.Strand V., Lipsky P. E., Cannon G. W. et al.: Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Resuls of two phase II studies. Arthritis Rheum. 1993; 36: 620630.

68.Sturfelt G., Mousa F., Jonsson H. et al.: Reccurent cerebral infarction and the antiphos-pholipid syndrome: effect of intravenous gammaglobulin in patient with systemic lupus erythematosus. Ann. Rheum. Dis. 1990; 49: 939-941.

69.Tomer Y., Blank M., Scoenfeld Y.: Supression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies. Athritis Rheum. 1994; 37: 1236-1244.

70.Ueno Y., Sohma Т.: Alpha interferon induced nodular rheumatoid arthritis in renal cell carcinoma. Ann, Intern. Med. 1992; 117: 266-267.

71.Van der Lubbe P., Reiter C., Breedveld F. C. et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 1993; 36: 1375-1379.

72.Vandenbroucke J. P., Hazevoet H. M., Cats A.: Survival and death in rheumatoid arthritis: a 25 year prospective follow up. J. Rheumatol. 1984; II: 158-161.

73.Veys E. M., Mielants H., Verbuggen G., Keyser F.: Intervention with immunomodulatory agents: new pharmacological development. Bailliere's Clin. Rheumatol. 1992; 6: 455-484.

74.Veys E. M., Millants U., Jerbrugger G. et al.: Recombinant IFN-gamma in rheumatoid arthritis. A doubleblind study. Clin. Exp. Rheumatol. 1987; 5 (suppl. 2): 53.

75.Wacholtz M., Lipsky P. E.: Treatment of lupus nephritis with CD5 plus, an immunoconjugate of an antiCD5 monoclonal antibody and ricin A chain. Arthritis Rheum., 1992; 35: 837-839.

76.Wahl S. M., Allen J. B., Ohura D. E. et al.: IFN-gamma inhibits inflammatory cell recruitment and evolution of bacterial cell wall-induced arthritis. J. Immunol. 1991; 146: 95-100.

77.Waidmann H.: Manipulation of T-cell responses with monoclonal antibodies. Annual Rev. Immunol. 1989;